IDH-mutant tumors are now classified as astrocytomas or oligodendrogliomas depending on other markers and, in general, the presence of IDH-mutant genes confers a better prognosis and an increase in life expectancy for the patient. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).